Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 1/20 | 0.35 |
| ▸ | MET | P08581 | 1/20 | 0.31 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15375455 | 0.88 | — | — | |
| SCHEMBL31586679 | 0.73 | HDAC8 (0.38) | CNR2PTGER4 | |
| SCHEMBL31118779 | 0.71 | PTGER4 (0.35) | PTGER4 | |
| SCHEMBL22337751 | 0.70 | KEAP1 (0.39) | PTGER4 | |
| SCHEMBL38655915 | 0.69 | NPC1 (0.32) | — | |
| SCHEMBL26445841 | 0.68 | NAMPT (0.45) | — | |
| SCHEMBL26449157 | 0.67 | AR (0.49) | — | |
| SCHEMBL20985958 | 0.67 | KDM4E (0.44) | — | |
| SCHEMBL26935472 | 0.67 | PKM (0.42) | CNR2 | |
| SCHEMBL31305972 | 0.66 | GRM2 (0.41) | CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2299816-B1 | INHIBITORS OF JANUS KINASES | MERCK SHARP & DOHME (US) | 2013-11-13 | — | — | EP | disclosed |
| US-8344144-B2 | Inhibitors of Janus kinases | MERCK SHARP & DOHME CORP. (US) | 2013-01-01 | — | — | US | disclosed |
| US-8344144-B2 | Inhibitors of Janus kinases | MERCK SHARP & DOHME CORP. (US) | 2013-01-01 | — | — | US | disclosed |
| US-8344144-B2 | Inhibitors of Janus kinases | MERCK SHARP & DOHME CORP. (US) | 2013-01-01 | — | — | US | disclosed |
| US-20110082136-A1 | INHIBITORS OF JANUS KINASES | MERCK SHARP & DOHME LLC | 2011-04-07 | — | — | US | disclosed |
| US-20110082136-A1 | INHIBITORS OF JANUS KINASES | MERCK SHARP & DOHME LLC | 2011-04-07 | — | — | US | disclosed |
| US-20110082136-A1 | INHIBITORS OF JANUS KINASES | MERCK SHARP & DOHME LLC | 2011-04-07 | — | — | US | disclosed |
| WO-2009155156-A1 | INHIBITORS OF JANUS KINASES | MERCK & CO., INC. (US) | 2009-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110082136-A1 | INHIBITORS OF JANUS KINASES | JAK2, JAK3, JAK1 | CNR2 4138/4885MET 2431/4885PTGER4 2619/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.